Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference25 articles.
1. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl. 6):1–158.
2. Buckner TW, Witkop M, Guelcher C, et al. Impact of hemophilia B on quality of life in affected men, women, and caregivers—assessment of patient-reported outcomes in the B-HERO-S study. Eur J Haematol. 2018;100(6):592–602.
3. Berntorp E, LeBeau P, Ragni MV, et al. Quality of life in a large multinational haemophilia B cohort (The B-Natural study)—unmet needs remain. Haemophilia. 2022;28(3):453–61.
4. Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105(3):545–53.
5. European Medicines Agency. Alprolix® Summary of Product Characteristics 2021. https://www.ema.europa.eu/en/documents/product-information/alprolix-epar-product-information_en.pdf. Accessed 23 Mar 2023.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献